title: Novel oral anticoagulants in atrial fibrillation: which novel oral anticoagulant for which patient?
abstract: Atrial fibrillation is the most common rhythm disorder and represents a major public health problem because it carries an increased risk of arterial thromboembolism and ischemic stroke. Current european society of cardiology guidelines recommend to stratify atrial fibrillation patients according to the CHA2DS2-VASc score and to administer anticoagulation, preferably with novel oral anticoagulants, that is, dabigatran, rivaroxaban, or apixaban, if the CHA2DS2-VASc score is at least 1. All novel anticoagulants have shown the same, if not greater, efficacy and safety as warfarin, with some advantages. The choice among the novel oral anticoagulants depends on their different pharmacokinetic profile, patients' stroke and bleeding risk, comorbidities, drug tolerability and costs and, finally, patients' preferences.
authors: aDepartment of Experimental and Clinical Medicine, University of Florence bSOD Patologia Medica, AOU Careggi, Florence cDepartment of Clinical Medicine and Surgery, University of Naples 'Federico II', Naples, Italy.
authors: Domenico
authors: D
authors: Prisco
authors: Caterina
authors: C
authors: Cenci
authors: Elena
authors: E
authors: Silvestri
authors: Lucia
authors: L
authors: Ciucciarelli
authors: Giovanni
authors: G
authors: Di Minno
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D017410:Practice Guidelines as Topic; D012720:Severity of Illness Index; D020521:Stroke / Q000517:prevention & control
chemical_list: D000925:Anticoagulants